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Background: Among people living with HIV (PLHIV) on antiretroviral therapy (ART), it is important to determine
how quality of life (QOL) may be improved and HIV-related stigma can be lessened over time. This study assessed
the effect of peer support on QOL and internal stigma during the first year after initiating ART among a cohort of
PLHIV in north-eastern Vietnam.
Methods: A sub-sample study of a randomised controlled trial was implemented between October 2008 and
November 2010 in Quang Ninh, Vietnam. In the intervention group, participants (n = 119) received adherence
support from trained peer supporters who visited participants’ houses biweekly during the first two months,
thereafter weekly. In the control group, participants (n = 109) were treated according to standard guidelines,
including adherence counselling, monthly health check and drug refills. Basic demographics were measured at
baseline. QOL and internal stigma were measured using a Vietnamese version of the WHOQOL-HIVBREF and
Internal AIDS-related Stigma Scale instruments at baseline and 12 months. T-tests were used to detect the
differences between mean values, multilevel linear regressions to determine factors influencing QOL.
Results: Overall, QOL improved significantly in the intervention group compared to the control group. Among
participants initiating ART at clinical stages 3 and 4, education at high school level or above and having experiences
of a family member dying from HIV were also associated with higher reported QOL. Among participants at clinical
stage 1 and 2, there was no significant effect of peer support, whereas having children was associated with an
increased QOL. Viral hepatitis was associated with a decreased QOL in both groups. Lower perceived stigma
correlated significantly but weakly with improved QOL, however, there was no significant relation to peer support.
Conclusion: The peer support intervention improved QOL after 12 months among ART patients presenting at
clinical stages 3 and 4 at baseline, but it had no impact on QOL among ART patients enrolled at clinical stages 1
and 2. The intervention did not have an effect on Internal AIDS-related stigma. To improve QOL for PLHIV on ART,
measures to support adherence should be contextualized in accordance with individual clinical and social needs.
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The HIV epidemic in Vietnam is in a concentrated stage,
with an estimated HIV prevalence of 0.53% in 2010 [1].
Antiretroviral therapy (ART) has been scaled-up in
Vietnam since late 2005 with funding through programs
such as the US President’s Emergency Plan for AIDS
Relief (PEPFAR) and Global Fund to fight AIDS, Tubercu-
losis and Malaria (GFATM). By December 2010, about
49,492 persons living with HIV (PLHIV) in Vietnam had
access to free ART [2].
The world-wide scale-up of ART has decreased the in-
cidence of new HIV infection and reduced AIDS-related
deaths substantially [3]. With an increased prevalence of
PLHIV on life-long ART, it is becoming increasingly im-
portant to determine which factors contribute to a better
quality of life (QOL). While people are living longer,
they may be living with increased health-challenges
related to HIV disease, the side effects of treatment or
emerging concurrent morbidities related to HIV or
aging. Hence, despite living longer, individuals may not
always be ‘living well’. Quality of life has become an es-
sential outcome to consider in the overall health and
well-being of people living with HIV. Whereas it is well
documented that ART improves not only clinical out-
comes but also QOL within the first year [4,5], conclu-
sions on what other factors (besides the ART itself ) can
contribute to a higher QOL are diverse [6,7]. Several fac-
tors have been identified as contributing to better QOL
among PLHIV, including social support [8,9], spiritual
well-being [9], education level [10,11], not being an
injecting drug user [12,13] and having good adherence
to ART [14,15]. Meanwhile, other factors such as HIV-
related stigma [16-18], non-disclosure of one’s HIV sta-
tus have been reported to negatively affect QOL [19].
Due to the strong relationship between QOL and
many important indicators for treatment success, QOL
has been widely applied in evaluating the impact of
HIV-related interventions among different populations
[20,21].
In settings with heavy HIV-related stigma and dis-
crimination and limited health care resources, such as
Vietnam [22], scaling up HIV care faces challenges,
including shortages of health care personnel willing to
work with HIV-infected individuals resulting in heavy
workloads and constrained support to patient adher-
ence. To counter this, community-based peer support
interventions have sought to improve adherence to
ART, to lessen internal HIV-related stigma as well as
to improve treatment outcomes such as QOL [23].
However, to date, there is no available data evaluating
such an intervention in Vietnam.
In this randomized controlled trial, we assess the im-
pact of peer support on QOL and internal stigma for
PLHIV after 12 months on ART.Methods
General study design
This study focusing on QOL is a sub-sample of a cluster
randomized controlled trial aiming to assess the impact
of peer support on viral suppression and resistance de-
velopment among patients in Quang Ninh province in
north-eastern Vietnam (DOTARV).
Study setting
The study was conducted at four outpatient clinics
(OPC) in Quang Ninh, a province in the northeast of
Vietnam with a population of 1.1 million. Quang Ninh’s
economy is rapidly growing and mainly based on indus-
tries such as coalmines, cement plants and harbours as
well as tourism within the famous Ha Long Bay. It is
also the area that is hardest hit by the HIV epidemic in
Vietnam, with an estimated HIV prevalence of slightly
above 1% among 15-49-year-olds [24].
Sampling and participants
The study sample was selected from four districts in
Quang Ninh province, which consisted of 71 communes
(28 urban and 43 rural). The total population of the 71
communes was 612,541 in 2009. Cluster-based sampling
at the level of the commune was employed in order to
minimize contamination between patients living near
each other. In cluster sampling, the 71 communes were
randomised to either intervention (36 communes) or
control (35 communes), after an initial matching accord-
ing to rural–urban, population and vicinity to hospital.
In both intervention and control communes, all patients
who came from the same commune were then treated
similarly in a standardized way according to the study
protocol. The study enrolled HIV positive patients who
were ARV-naïve and eligible to initiate ART according
to the Vietnamese national guidelines at the time of the
study. Inclusion criteria were as following: clinical stage
4 of HIV disease (AIDS related illnesses) regardless of
CD4+ count, clinical stage 3 (severe opportunistic infec-
tions) with CD4+ <350/μl, clinical stage 1 and 2 (asymp-
tomatic or mild infection) with CD4+ count of <200/μl
[25] . Exclusion criteria were pregnancy, age under 18 or
above 60, mental illness and institutionalization. While
the larger DOTARV study began in 2007, the present
sub-study focusing on QOL and internal stigma included
all DOTARV participants recruited from October 2008
to November 2009. Two-hundred seventy-five partici-
pants were consecutively selected from both the inter-
vention and the control groups (i.e. all persons eligible
for ART and meeting inclusion criteria from both inter-
vention and control communes were enrolled in this
sub-study). Among these, 24 died within six months of
ART initiation, twelve patients did not come for the
interview at twelve months and eleven dropped out of
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due to heroin trafficking. A total of 228 participants
responded to the interview both at baseline and at
twelve months.
Control
Those individuals who were randomized to the con-
trol arm of the study received standard care as per
normal government health care standards for patients
initiating ART. This included adherence counselling
and readiness training provided by the medical staff
of these OPCs at individual level (three times) and
at group level (three times) prior to starting ART.
Health checks, adherence assessment and drug refills
were carried out monthly at the outpatient clinic. All
patients would report their obstacles/barriers to ART ad-
herence (if any) to health staff at the OPCs at monthly vis-
its. In case non-adherence to ART was identified by
health staff, adherence counselling would be provided in-
stantly on location.
The adherence assessment in this study was based on
the self-reports from the patients as well as pills counts.
These were both compared to the amount of the pills
that should have been taken using the criteria recom-
mended by WHO [26]. The adherence assessment then
referred to: good adherence (patient forgot to take doses
less than four times per month); moderate adherence
(patient forgot to take doses between 4–8 times per
month) and poor adherence (patient forgot to take doses
more than 8 times per month).
Intervention
Individuals in the intervention arm of the study received
standard care as described above and also received peer
support from trained PLHIV who were taking ART.
These peers functioned as “external supporters” for
patients initiating ART and performed biweekly visits
during the initial two months of ART, when drug-taking
habits were being formed. After two months, the visits
were reduced to once per week (if treatment adherence
was good) or intensified to become more frequent (if ad-
herence was poor). To facilitate the peer support activ-
ities and ensure that the adherence support was carried
out properly, a standardized checklist was developed by
the research group together with a group of PLHIV who
were on ART. The checklist was used to guide the peer
supporter to ask questions in a standardized order and
manner. During each visit, the external supporter went
through this standardized checklist including questions
about general well-being, signs/symptoms since the last
visit, psychological problems or adverse drugs reactions
as well as adherence to therapy since the last visit. The
checklist was only applied in the intervention group and
hence it was not used for data collection or for monitoringthe effects of the intervention. Patients and family mem-
bers were encouraged to report all constraints/obstacles
to ART adherence. Barriers to ART adherence identified
during the visiting were discussed between the peer
supporter, the patient and family members to determine
a feasible solution and (if necessary) health staff at the
outpatient clinic were contacted for advice. Problems
identified by peer supporters such as common barriers,
suggestions for changing dose-taking schedules, behav-
iour of family member towards peer supporter (if any)
were discussed among the research group at monthly
meetings.
Measurement tools
Study tools administered to both intervention and con-
trol participants included:
The WHOQOL-HIVBREF includes questions respond
to the definition of Quality of Life as Individuals’
perception of their position in life in the context of the
culture and value system in which they live and in
relation to their goals, expectation, standards and
concerns. This measurement produced scores on the
patients’ self-reported judgement of six different
domains of QOL including: Physical (4 facets: pain,
energy, sleep, symptoms); Psychological (5 facets:
positive feelings, cognitive, self- esteem, bodily image,
negative feelings); Social Relationships (4 facets:
personal relationships, social support, sexual activity,
social inclusion); Level of Independence (4 facets:
mobility, daily activities, dependence on medication,
work capacity); Environment (8 facets: physical safety
and security, home environment, financial resources,
health and social care, opportunities for acquiring new
information, opportunity for leisure activities, physical
environment, transport) and Spirituality/Personal
Beliefs (4 facets: forgiveness and blame, concern about
the future, death, spirituality). The patients answered
each question using a 5-level Likert scale. Among
these, scores of questions with negative direction
(negative feelings, pain and discomfort, dependence
on medicine, death) were reversed to make higher
scores generally indicate better QOL. The score
of each domain ranged between 4 and 20. These scores
could also be added up to produce an overall score.
The higher scores indicated better QOL [27]. The
difference between the score at 12 months and the
score at baseline was then used to express the change
in QOL (both for each separate domain and for the
overall score). We strictly followed the protocol
provided by the WHOQOL-HIV Group to translate
and using forward-backward translation with
subsequent reviews and discussions within the
research groups.
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focused on self-blame and concealment of HIV status
[28]. This measurement assessed if patients agreed with
statements including: It is difficult to tell people about
my HIV infection; Being HIV positive makes me feeling
dirty; I feel guilty that I am HIV positive; I am ashamed
that I am HIV positive; I sometimes feel worthless
because I am HIV positive; and I hide my HIV status
from others. Participants responded to each question
by agree = 1 or disagree = 0. The total scores ranged
from 0 to 6. Lower scores at 12 months means lessened
stigma over time.
Both WHOQOL-HIVBREF and Internal AIDS-related
stigma measurement tools were pre-tested, revised and
validated prior to beginning data collection.
Baseline characteristics of the participants were
collected through a baseline questionnaire that
included socioeconomic characteristics (age, sex,
education level, occupation, marital status, number of
children, housing, income) and HIV-related
characteristics (HIV transmission routes, the duration
of knowing their HIV status, other family member
infected with HIV or died from HIV, alcohol and drug
use behaviours, hepatitis co-infection, clinical staging).
Data on QOL and internal AIDS-related stigma were
collected in a separate room at the outpatient clinic
through self-administered questionnaires after partici-
pants were provided with instructions on how to fill
them in by a member of the health staff. These assess-
ments were carried out at initiation of treatment and
then every four months in connection to the partici-
pants’ scheduled monthly drug pick-up with a planned
follow-up time of one year.
Statistical analysis
Data collected were processed and analysed using SPSS
version 13 and STATA version 10. Proportions, means
and standard deviations (SDs) were used for the descrip-
tive analysis. Chi-square tests were performed to exam-
ine the difference between proportions (sex, age
distribution, marital status, occupations, education level,
current and past IDU, clinical stage, member of family
infected with HIV or died from HIV). WHOQOL-
HIVBREF scores and stigma scale scores were assessed
for normal distributions. T-tests were used to detect the
difference between mean values of QOL scores or
Stigma scores in both related samples model and inde-
pendent samples model. Pearson’s correlation coefficient
was used to evaluate the correlation between quantita-
tive variables [29]. Stepwise multiple linear regression and
multilevel linear regression methods were used to estimate
the causal relationship between QOL change between
baseline and 12 months and independent variables. Weused default cut-offs provided by SPSS in stepwise
multiple linear regression (0.05 to enter in the model and
0.10 to be removed from the model) to choose the most
influential independent variables. Then multilevel linear
regression was applied to justify the effects of intra cluster
correlation. Intra cluster correlation coefficients (ICCs)
were calculated to evaluate the similarity of QOL within
clusters (communes). In all the tests and regression mod-
els, p-values less than 5% were considered significant.
Longitudinal approach was attempted in order to take the
values of the QOL at different time points (baseline,
4 months, 8 months, 12 months) into account. However,
due to the small sample size, the change in QOL during
the 4 months intervals was not significant. Thus, only the
results related to QOL at baseline and 12 months are pre-
sented here.
Results
Among 228 ARV-naïve patients recruited to the QOL
study within the DOTARV project from October 2008
to November 2009, there were 119 in the intervention
group and 109 in the control group. Characteristics of
the study participants at baseline are described in
Table 1. There were no significant differences in these
characteristics between the two groups.
QOL in the intervention and control groups
Overall, QOL of the whole cohort seemed to increase
over time, with a mean score of 76.5 at baseline and 77.3
after one year of ART, but this difference was not signifi-
cant (p = 0.295). However, stratification by intervention–
control groups and clinical stages showed different
patterns.
Table 2 shows the results of the QOL scores that
changed over time within each group. In the intervention
group, overall QOL scores and QOL scores of physical
and independent capacity increased mainly among
patients who presented at clinical stages 3 and 4. Among
patients who presented at clinical stages 1 and 2,
QOL scores increased slightly in independent capacity
(p = 0.033) but decreased in the domain of environ-
ment (p = 0.001). In the control group, QOL increased
only in independent capacity among patients pre-
sented at clinical stages 3 and 4.
Table 3 shows the results of comparison of QOL scores
changed over time between groups. Among participants
enrolled with more severe immunosuppression at baseline
(clinical stage 3 and 4), there was a significant association
between peer support and improved overall QOL
(p= 0.034), more specifically the QOL domains of physical
well-being (p= 0.007), level of independence (p= 0.038)
and spirituality (p= 0.029). Meanwhile, among partici-
pants those were less symptomatic when beginning ART
(clinical stage 1 or 2), there were no significant differences







≤ 35 65.5 73.4 0.119
> 35 34.5 26.6
Sex
Male 65.5 70.6 0.410
Female 34.5 29.4
Education
Secondary or less 45.4 52.3 0.297
High school or higher 54.6 47.7
Occupations
Unemployed 16 23.9 0.135
Employed 84 76.1
Marital status





≤ 30 USD 22 32.1 0.072
> 30 USD 78 67.9
Having children
Yes 48.7 54.1 0.416
No 51.3 45.9
Other PLHIV in family
Yes 39.5 38.5 0.882
No 60.5 61.5
Someone in family died of AIDS
Yes 26.9 20.2 0.234
No 73.1 79.8
Reported mode of HIV infection
Having sex 52.1 52.8 0.320
IDU 36.1 42.2
Do not know 11.8 5.0
History of IDU
Yes 47.1 45.9 0.858
No 52.9 54.1
Current IDU
Yes 9.2 5.5 0.283
No 90.8 94.5
Hepatitis C and/or B co-infection
Yes 28.6 22.9 0.332
No 71.4 71.1
Clinical staging
Stage 1 or 2 47.1 48.6 0.813
Stage 3 or 4 52.9 51.4
*: Chi-square test in proportions comparison.
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specific domains (Table 3).
Factors influencing QOL improvement
Table 4 presents factors related to overall QOL by Uni-
variate analysis. All the factors included in Table 4 which
had a p-value < 0.20 (showing a possible correlation with
the main outcome) were added in regression models.
After stepwise multiple linear regressions, the most in-
fluencing independent variables were taken into of
multilevel linear regression analysis with individuals as
units of level 1 and communes as units of level 2
(Table 5). Intra cluster correlation coefficients (ICCs) of
12-months changing of overall QOL as well as of all
domains are presented in Table 5.
Results among patients presented at clinical stages 3 and 4
Participants had significant improvement in overall
QOL after 12 months if they had higher education
(p = 0.01), previously had an experience of a family mem-
ber dying from HIV (p < 0.001) or received peer support
(“borderline” p= 0.080). The influences of intervention
and other factors to specific domains are also described
in Table 5. People with higher education had significant
improvement in Psychological wellbeing (p = 0.044)
and Spirituality/personal beliefs (p = 0.001). Meanwhile,
experience of a family member dying from HIV gave
positive contributions for almost all domains of QOL
Conversely, Hepatitis C and/or B co-infection was sig-
nificantly associated with decreased Physical wellbeing
(p = 0.021).
Results among patients presenting at clinical stages 1 and 2
Peer support did not appear to have any impact (Table 5).
In this group, for those with hepatitis B and/or C co-
infection, overall QOL decreased significantly (p = 0.017)
after 12 months of follow-up, specifically for the QOL
domains of psychological well-being (p = 0.043), level of
independence (p = 0.014), social relations (p = 0.011) and
environment aspect (p < 0.001). Whilst, having children
in family can help to have better Spirituality/personal
beliefs (p = 0.004) and then to improve QOL (p = 0.036).
QOL and internal AIDS-related stigma
The average internal AIDS-related stigma scores for
both intervention and control groups) at baseline and
after 12 months were 3.21 (SD= 1.96) and 3.27 (SD=
1.80) respectively. The internal AIDS-related stigma did
not differ between the intervention and control groups
or between the different clinical stage groups after
12 months. There was a significant association between
value of QOL change over time and changes in internal
AIDS-related stigma (p < 0.001). However, this is not a
strong correlation with a correlation coefficient of −0.36.
Table 2 Change in QOL score after 12 months of ART, by QOL domains and intervention versus control group
Clinical stage QOL by domain Control group Intervention group
At baseline Mean (SD) After 12 months Mean (SD) P-value* At baseline Mean D) After12 months Mean (SD) P-value*
Clinical1 & 2 Physical 12.87 (2.82) 13.57 (1.65) 0.087 13.45 (2.43) 13.87 (2.04) 0.274
Psychological 12.53 (2.71) 13.05 (1.69) 0.123 13.19 (2.13) 12.93 (1.9) 0.425
Level of Independence 11.93 (2.34) 12.67 (1.72) 0.061 12.46 (1.68) 13.18 (1.93) 0.033
Social Relationships 12.72 (2.44) 12,31 (1.63) 0.166 12.79 (2.18) 12.36 (1.68) 0.206
Environment 12.44 (2.56) 12.24 (2.04) 0.590 13.29 (2.31) 12.19 (1.85) 0.001
Spirituality/Personal Beliefs 13.11 (3.34) 13.89 (2.89) 0.272 13.18 (3.61) 13 (3.06) 0.654
Overall QOL Scores 75.61 (12.65) 77.74 (7.77) 0.337 78.35 (10.62) 77.53 (9.05) 0.533
Clinical 3 & 4 Physical 12.76 (2.21) 13.04 (2.08) 0.419 12.51 (2.56) 14.16 (1.90) < 0.001
Psychological 13.0 (1.83) 12.26 (2.11) 0.051 12.69 (2.52) 12.70 (1.89) 0.970
Level of Independence 11.71 (1.76) 12.47 (2.10) 0.010 11.52 (2.05) 13.29 (2.09) < 0.001
Social Relationships 12.44 (1.92) 12.1 (1.76) 0.491 12.98 (2.45) 12.37 (1.29) 0.073
Environment 12.44 (1.93) 11.91 (1.79) 0.107 12.66 (2.31) 12.4 (2.12) 0.412
Spirituality/Personal Beliefs 14.47 (3.17) 13.36 (2.92) 0.107 13.03 (2.85) 13.78 (2.47) 0.14
Overall QOL Scores 76.82 (8.26) 75.36 (9.6) 0.438 75.39 (10.38) 78.69 (8.47) 0.023
*: T-test for mean comparison of related samples.
























Table 3 Mean of difference after 12 months of ART between groups
Clinical 1 & 2 Clinical 3 &4
Control Mean (SD) Intervention Mean (SD) P-value* Control Mean (SD) Intervention Mean (SD) P-value*
QOL
Physical 0.6792 (2.83) 0.4286 (2.90) 0.649 0.3036 (2.78) 1.6508 (2.58) 0.007
Psychological 0.5585 (2.59) −0.2571 (2.39) 0.090 −0.7571 (2.84) 0.0127 (2.66) 0.130
Level of Independence 0.6792 (2.57) 0.7143 (2.44) 0.942 0.8214 (2.28) 1.7619 (2.55) 0.038
Social Relationships −0.5283 (2.73) −0.4286 (2.50) 0.843 −0.2321 (2.5) −0.6190 (2.69) 0.421
Environment −0.2170 (2.91) −1.0982 (2.36) 0.085 −0.5089 (2.32) −0.2540 (2.44) 0.562
Spirituality/Personal Beliefs 0.5660 (3.70) −0.1786 (2.96) 0.248 −0.8715 (4.00) 0.7460 (3.96) 0.029
Overall QOL 1.7377 (13.06) −0.8196 (9.76) 0.248 −1.2482 (11.95) 3.2984 (11.21) 0.034
*: T-test for mean comparison of independent samples.
QOL: higher score: better QOL.
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on ART also reported decreased stigma and vice versa.
Discussion
This is the first study, to our knowledge, that shows a
positive effect of peer support on QOL among severely
immunosuppressed patients initiating ART in the context
of a randomised controlled trial. We found that peer sup-
port had a very different effect on QOL depending on the
patient’s clinical condition when starting ART. Those with
severe immunosuppression and opportunistic infections
(clinical stages 3 or 4) who received extra adherence sup-
port from a trained peer supporter reported significantly
improved QOL after 12 months on ART compared to a
control group who received standard care. This improve-
ment in the intervention group was not found among
patients who were asymptomatic or who had mild symp-
toms (clinical stage 1 or 2) when ART was initiated.
QOL was particularly improved among severely im-
munosuppressed intervention-group patients in the
domains that relate to the clinical condition such as
physical well-being, level of independence and spiritual-
ity (perceptions about the future or worrying about
death). For other QOL domains (psychology, social rela-
tionships and environment) improvement appeared to
depend on individual factors such as level of education
and earlier experience of a family member dying from
HIV rather than on contact with a peer supporter. The
improvement in QOL in some segments of the interven-
tion group might have been because the peer supporters
were able to utilise their own experiences as PLHIV to
empathically listen, understand, advise and assist the
patients to problem-solve. In addition, as the peer sup-
porters had received training, they could act as intermedi-
aries between patients and health care providers [30],
giving information, counselling and assisting patients to
contact health staff when needed [23], particularly in cases
the patients experienced severe symptoms that could
influence QOL negatively [31].While QOL became better over time among patients
started ART in advanced stage of HIV/AIDS (clinical
stage 3 or 4), the patients who had not experienced
AIDS and opportunistic infections (clinical stage 1 or 2)
often showed a decline QOL after baseline [32]. They
might have perceived the regular visits of the external
supporters as annoying or threatening due to the risk of
involuntary disclosure to neighbours, which might have
reduced some aspects of QOL [19]. Other explanations
such as challenges with starting ART per se, including
the treatment associated stigma we found in an earlier
study [23] and the issue of being dependent on life-long
regular medicine intake while not being physically very
sick, might also play a role. As opposed to the patients
in stage 3 or 4, who experienced physical improvement,
these patients have less clear evidence of the positive
side of the medication. Alternatively, one might perceive
that there could be a ceiling effect with the WHOQOL-
HIVBREF that might occur in the stage 1 and 2 group,
with baseline high QOL. However, we were surprised
that QOL was not higher among this group at baseline
and do not think that there was a significant “ceiling ef-
fect” in play during this evaluation.
Meanwhile the intervention improved QOL among
participants in the group with severe immunosuppres-
sion and opportunistic infections, there were no changes
regarding internal AIDS-related stigma scores neither in
the intervention nor in the subgroup with different clin-
ical stages. Stigma might be not directly influenced by
adherence support measures. In Vietnam there is a
strong association between HIV and “social evils” includ-
ing IDU and sex work as well as fear of HIV transmis-
sion [33]. A study carried out in Ho Chi Minh City,
Vietnam revealed that PLHIV often faced problems
getting a job, perceived unfair treatment in the work
place and experienced discrimination from health care
providers [34].
The decision to use peer support as an intervention
was taken as a result of focus group discussions with
Table 4 Changing of Overall QOL Scores after 12 months of ART and influencing factors by Univariate analysis
Factors Patients at Clinical stage 1 & 2 Patients at Clinical stage 3 & 4
Mean of difference P value* Mean of difference P value*
Sex Male −1.1149 0.078 0.2227 0.114
Female 2.8786 3.8161
Age >35 −1.3867 0.314 2.1975 0.495
=< 35 1.1114 0.6329
Occupation Unemployed 3.3500 0.24 1.4333 0.891
Employed −0.1549 1.1775
Education Secondary or less 1.7457 0.3080 −1.0789 0.046
High school or higher −0.5413 3.2161
Having children Yes 2.5875 0.033 1.2738 0.913
No −2.1327 1.0379
Income/month ≥30USD 3.2469 0.086 1.2500 0.958
<30USD −0.9197 1.1220
Other PLHIV in the family Yes 1.2143 0.520 3.1725 0.184
No −0.2217 0.1392
Someone in family died of AIDS Yes 0.7192 0.882 7.4926 0.001
No 0.3313 0.7000
Own a house Yes 3.6938 0.069 3.2419 0.253
No −0.6671 0.4126
Social support High 0.3203 0.919 2.3629 0.245
Low 0.5464 −0.1509
Hepatitis C and/or B Yes −5.9522 0.002 −2.3833 0.034
No 2.3880 2.6185
Alcohol use Yes −1.0579 0.295 0.7488 0.786
No 1.5386 1.3727
History IDU Yes −0.6667 0.356 0.0873 0.358
No 1.3828 2.0797
Current IDU Yes 1.8875 0.711 −1.400 0.499
No 0.3079 1.3682
Intervention Yes −0.8196 0.248 3.2984 0.034
No 1.7377 −1.2482
*: T-test for mean comparison of independent samples.
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ted in Vietnam and the majority of the participants had
been or were severely immunosuppressed with oppor-
tunistic infections. The effect of peer support on QOL
improvement depends on the clinical stages of patients
as shown by this study. This randomized controlled trial
implemented a common standardized intervention for
all patients, independent of clinical staging and severity
of disease and, therefore, may have some limitations.
However, the findings indicate a need to develop
appropriate intervention tools tailored according to the
severity of disease at ART initiation to enable contextua-
lization of the support to different strata of the patient
population. Based on our results, we cannot recommend
a general peer support intervention but rather an inter-
vention targeted to patients with advanced stages ofHIV infection. While there seem to have been benefits
for the patients in stage 3 and 4, there were no such
effects on the patients with less advanced disease. Pos-
sibly similar positive effects could be achieved by sup-
port to HIV positive clubs of various kinds, encouraging
twinning of patients for those who wish, group support
meetings at the hospital etc, rather than organized as
the individual resource-intensive process presented in
this study. With such an approach, patients’ needs could
be revaluated on a regular basis. For patients who initi-
ate ART when they are at clinical stage 1 or 2, adher-
ence support via a mobile phone text message may be
considered more appropriate than peer support in
some settings, as it might be perceived to interfere less
with patient privacy. This approach has been applied
successfully in several other contexts [35,36] and is
Table 5 QOL change after 12 months of ART in multilevel linear regression models










Overall QOL 28.6 42.7
Constant 0.979 0.672 −4.690 0.074
High school or higher education −2.537 −0.109 0.254 5.311 0.226928 0.010
Someone in family died of AIDS 1.762 0.066 0.487 8.776 0.314378 0.000
Having children 4.561 0.199 0.036 −0.486 −0.02076 0.810
Hepatitis C and/or B co-infection −6.460 −0.230 0.017 −2.764 −0.10861 0.214
Intervention −1.001 −0.044 0.689 4.156 0.177439 0.080
Physical 32.2 44.7
Constant 0.557 0.376 0.420 0.497
High school or higher education −0.767 −0.133 0.181 0.556 0.101 0.258
Someone in family died of AIDS −0.175 −0.026 0.789 1.204 0.184 0.037
Having children 0.840 0.148 0.132 −0.497 −0.091 0.304
Hepatitis C and/or B co-infection −0.204 −0.029 0.773 −1.229 −0.206 0.021
Intervention 0.223 0.039 0.758 1.359 0.247 0.014
Psychological 27.6 40.9
Constant 0.384 0.415 −1.221 0.037
High school or higher education −0.392 −0.077 0.420 1.013 0.184 0.044
Someone in family died of AIDS 0.722 0.123 0.195 1.411 0.214 0.018
Having children 0.800 0.160 0.091 −0.354 −0.064 0.478
Hepatitis C and/or B co-infection −1.199 −0.196 0.043 −0.540 −0.090 0.322
Intervention −0.495 −0.099 0.414 0.641 0.116 0.232
Level of independence 26.1 37.7
Constant 0.969 0.056 1.420 0.010
High school or higher education −0.798 −0.158 0.103 −0.286 −0.058 0.532
Someone in family died of AIDS 0.509 0.087 0.363 0.431 0.073 0.429
Having children 0.433 0.087 0.364 −0.551 −0.112 0.226
Hepatitis C and/or B co-infection −1.470 −0.241 0.014 −0.789 −0.147 0.113
Intervention 0.347 0.070 0.564 0.806 0.164 0.097
Social relation 21.5 33.5
Constant −0.516 0.377 −1.012 0.070
High school or higher education −0.304 −0.058 0.561 0.733 0.141 0.125
























Table 5 QOL change after 12 months of ART in multilevel linear regression models (Continued)
Having children 0.313 0.060 0.539 0.354 0.069 0.456
Hepatitis C and/or B co-infection −1.622 −0.255 0.011 −0.261 −0.046 0.615
Intervention 0.418 0.080 0.472 −0.414 −0.080 0.417
Environment 31.2 32.4
Constant −0.182 0.737 −1.155 0.040
High school or higher education −0.219 −0.041 0.657 0.849 0.179 0.065
Someone in family died of AIDS 0.213 0.034 0.705 1.096 0.194 0.038
Having children 0.442 0.083 0.358 0.114 0.024 0.799
Hepatitis C and/or B co-infection −2.315 −0.355 0.000 −0.276 −0.053 0.576
Intervention −0.315 −0.059 0.602 0.174 0.037 0.761
Spirituality/personal beliefs 22.3 32.0
Constant −0.530 0.444 −3.215 0.000
High school or higher education −0.051 −0.008 0.939 2.215 0.275 0.001
Someone in family died of AIDS 0.324 0.041 0.671 3.337 0.347 0.000
Having children 1.865 0.279 0.004 0.524 0.065 0.446
Hepatitis C and/or B co-infection 0.348 0.043 0.670 0.522 0.059 0.487
Intervention −0.778 −0.116 0.327 1.705 0.211 0.026
*: Test to compare regression coefficient to 0.
**: Difference between 12-month score and baseline score.
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in India [37].
Our results show that the intervention had a posi-
tive effect on QOL among those who were at clinical
stages 3 and 4. We have not assessed the intervention
from a cost effectiveness perspective, but the use of
peer-supporters is a comparably low-cost measure,
and our recommendation would be for the health sys-
tem to continue to work with peer-supporters inter-
ested in this job, and then to specifically use them
for support to patients at clinical stages 3 and 4, who
are starting ART.
A number of other independent factors shown to have
an impact on QOL in this study have also been demon-
strated by other studies. For example, people who ex-
perience less stigma are more likely to optimistically
assess their QOL in general [17,18,38]. The relationship
between co-infection with hepatitis B and/or C and
reduced QOL may be due to the fact that the major
symptoms of hepatitis B and C are caused by an immune
reaction; hence, with improved immunocompetence for
patients on ART, hepatitis symptoms may be more
pronounced [39-41]. This indicates the need for
improved hepatitis management for PLHIV on ART.
Patients who have higher education levels will achieve
better QOL [10], possibly as they are more integrated
in society and may have a better social network of
family and friends. It is difficult to explain why those
who witnessed the death of a family member due to
HIV had better QOL improvement. However, it might
have been that they valued their own lives and
improved health more after the grim experience of los-
ing a family member to HIV [42].
Contradicting findings from other studies, the findings
in this study did not show that reported intravenous
drug use, present or prior, influences QOL in any direc-
tion [12,43].
This study had some limitations. For example, factors
such as employment, income and marital status were
only collected at baseline and might not have accurately
reflected the influence of these factors on QOL if they
changed over time. Other limitations may include a ra-
ther high withdrawal rate (17%) and the potential con-
tamination which may have resulted in over or
underestimating the effect of the intervention on QOL.
However, as the withdrawal rate was similar in the two
groups and patients were randomized, these potential
effects can be presumed to be similar in the intervention
and control groups. By randomizing the 71 communes,
to increase the geographical spread, we assumed that the
risk for contamination was decreased or at least less
common as compared to an individual randomization
design. The main objective of the DOTARV project was
to assess whether peer support can improve patients’adherence to ART and decrease treatment failure rates.
Adherence could be an influencing factor of QOL in
either positive or negative way. Increased adherence
could result in greater suppression of the virus and re-
sult in increased quality of life [14,15] or greater adher-
ence might be associated with increased adverse effects
of medications resulting in decreased quality of life [31].
As this is an ongoing cohort that continues to be fol-
lowed, it may be possible to assess the co-variation of
QOL, adherence and clinical outcomes of the interven-
tion at a later stage. A potential weakness of our study is
the fact that a Minimal Clinically Important Difference
(MCID) has not been established for the WHOQOL-
HIVBREF instruments used. While studies on QOL in
relation to HIV and ART are now appearing from differ-
ent contexts in both low- and middle- income countries,
there are clearly contextual differences in indicators,
dependent on country of study [44]. Hence, we hope our
results will contribute to the further development of this
research area.
Conclusions
The peer support intervention improved QOL after
12 months follow up for patients who were enrolled on
ART with severely immunosuppressed condition (clin-
ical stages 3 and 4) but had no impact on QOL improve-
ment for patients enrolled with mild or no clinical
symptoms (clinical stages 1 and 2). Neither had the
intervention any effect on Internal AIDS-related stigma.
To improve QOL for PLHIV on ART, measures to sup-
port adherence should be contextualized in accordance
with the individual clinical and social needs of the
patient.
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